Completed Projects

HOME > R&D Pipeline > Current status > Completed Projects

KDDF-201612-09 Development of drug candidates for treatment of rheumatoid arthritis by optimization of SIS-1-derived lead compounds(Immunology, Protein) [04.27.2017]

PRINT

Development and Market Objectives

Our goal is to develop a candidate for a therapeutic agent for rheumatoid arthritis. We have successfully developed three lead compounds demonstrating superior arthritis improving efficacy through our prior study with high commercial efficacy and low antigenicity in small size (6 or 9 amino acids)  (KDDF-201404-04). In this study, we plan to perform "lead optimization" to derive a candidate with the highest efficacy and safety in the body among the three lead compounds in order to increase the possibility of develop peptide drugs to treat arthritis.

Unmet Medical Need & Target Patients

We selected Phase III patients as primary target patients. In patients failing treatment in Phase I and II, the other TNF inhibitor or other biological agents may be may be administered in Phase III. However, there are several side effects, such as the increased tolerance, the risk of infection, and patient’s economic burden due to long-term administration.

 

Our lead compounds are expected to treat RA disease at the initiation stage, since Treg activation will be involved as a key mechanism. In addition, fast onset can shorten the treatment period, reducing the risk of infection by long-term administration and reducing the patient's economic burden. Additionally, since the lead substance is a small peptide, antigenecity will be low. Therefore, it is anticipated that drug resistance problems of Phase III patients will also be solved.

 

In our previous study, we confirmed that the action of lead compound is likely to be a TNF independent response, and we expect to maximize the therapeutic effect in combination with TNF inhibitors. Therefore, after this, all TNF inhibitor-treated patients will be selected as secondary target patients, thus securing the possibility of market expansion.

 

Status

Generation of three lead compounds for RA therapy in CIA mouse model

 

Verifying the mode of action of three lead compounds for RA treatment (Inhibitory function of three lead compounds toward polarized Th17 cells and osteoclast differentiation)

 

Identification of two targets for three lead compounds binding

 

Establishment of the stability of three lead compounds in human plasma

Intellectual Property

PCT application PCT/KR2017/002116

 

PCT application PCT/KR2017/002117

 

PCT application PCT/KR2013/1005912

 

Domestic registration 10-1510941

 

Domestic application 10-2016-0028227

 

Domestic application 10-2016-0028229

 

Domestic application 10-2012-0072513

 

Progressing with patent protection in 10 major countries

Competitive Advantages

Development of a novel therapeutic target that is highly effective on TNF inhibitor refractory patients by targeting a different mechanism to that of TNF inhibition.

 

‘First-in-class’ investigation of the therapeutic potential of Erdr1 which has been implicated with anti-cancer and anti-inflammatory effects

 

Domestic licensing-out is in progress via joint research with domestic and overseas pharmaceutical companies through continuous contact. The possibility of a successful international licensing deal is high.

Indication

Rheumatoid Arthritis

Research Period

2017.4.1-2018.8.31

Company

Sookmyung Women’s University

Developmental Stage

Optimization

Additional Information

Contact Information

Contact
Address Company Name: Sookmyung Women’s University
WebSite Homepage: http://snowe.sookmyung.ac.kr/club/cdhkor Contact Person: Prof. Daeho Cho
E-mail: cdhkor@sookmyung.ac.kr Contact: +82-2-710-9416

Related Projects

Related Project
list
Update to 2013 © KOREA DRUG DEVELOPMENT FUND. ALL RIGHTS RESERVED. QR Code